98%
921
2 minutes
20
The changes in lgG antibody levels to hepatitis B surface antigen (HBsAg) and in antibody to HBsAg (anti-HBs) seroconversion rates due to different dosages of hepatitis B vaccine (HepB) were compared in 2106 children. Children who had been previously vaccinated as infants with HepB were revaccinated at 5-15 y of age, after which the antibody titers were determined. After the first booster dose, the anti-HBs seroconversion rate (defined as an anti-HBs ≥10 mIU/ml) with 10 μg of HepB (93.6%) was significantly greater than the rate with 5 µg of HepB (90.3%) (P<0.05); the anti-HBs seroconversion rate in 10-15-y-old boys vaccinated with 10 μg of HepB (90.9%) was significantly greater than the rate with 5 µg of HepB (84.3%) (P<0.05). The anti-HBs seroconversion rates after the third booster dose with 5 or 10 μg of HepB were greater than those after the first booster dose (99.6% and 99.7%, vs. 90.3% and 93.6%, P<0.05); as was the corresponding GMTs (658 ± 4 mIU/ml and 2599 ± 3 mIU/ml, vs. 255 ± 11 mIU/ml and 877 ± 11 mIU/ml [P<0.05]). The immunization effects of booster vaccination with 3 doses of HepB with 5 or 10 µg are effective; a single booster dose with 10 µg of HepB for 10-15-y-old boys and with 5 or 10 µg of HepB for 5-9 y old boys and for 5-15-y-old girls are effective in generating protective antibody against HBV; however, for anti-HBs-negative children after a single dose of booster, 3 doses are needed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185892 | PMC |
http://dx.doi.org/10.4161/hv.26936 | DOI Listing |
Diagn Microbiol Infect Dis
September 2025
French National Reference Center for Hepatitis B, C and delta Viruses, Department of Virology, Hôpital Henri Mondor, Créteil, France; INSERM U955, Créteil, France. Electronic address:
Measurement of hepatitis B virus (HBV) DNA levels is the standard of care for diagnosis active HBV infection, assessing disease severity and prognosis, and guiding treatment decisions and monitoring response to therapy. In the study, the analytical and clinical performance of the ELITe InGenius System for quantifying HBV DNA was evaluated. A total of 377 of archived EDTA plasma or serum specimens were tested.
View Article and Find Full Text PDFHIV Med
September 2025
Department of Medical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Türkiye.
Introduction: Monitoring transmitted drug resistance is crucial for guiding first-line antiretroviral therapy (ART) and controlling the rising HIV epidemic in Türkiye. This study aimed to determine the prevalence of transmitted antiretroviral resistance to protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs) and capsid assembly inhibitors (CAIs). We also assessed the distribution of HIV-1 subtypes and circulating recombinant forms (CRFs) at one of the main national referral centres in Türkiye.
View Article and Find Full Text PDFAliment Pharmacol Ther
September 2025
Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Aliment Pharmacol Ther
September 2025
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
PLOS Glob Public Health
September 2025
Department of Molecular Medicine, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ashanti Region, Ghana.
Coinfection of humans with Hepatitis B Virus (HBV) and non-viral pathogens may worsen the outcome of HBV infection on the liver. This study determined the prevalence of Heliobacter pylori, Salmonella typhi, Plasmodium falciparum, and Toxoplasma gondii among Hepatitis B Virus (HBV)-infected persons in the Greater Accra Region (GAR) of Ghana and examined how such co-infections might affect the levels of selected liver function markers (LFM). The design was cross-sectional, involving 120 HBsAg-positive HBV-infected persons.
View Article and Find Full Text PDF